Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers

Post, 2003, Replicative oncolytic adenoviruses in multimodal cancer regimens, Hum Gene Ther, 14, 933, 10.1089/104303403766682205 Liu, 2007, Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress, Nat Clin Pract Oncol, 4, 101, 10.1038/ncponc0736 Prestwich, 2009, The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon, Hum Gene Ther, 20, 1119, 10.1089/hum.2009.135 Davison, 2003, Genetic content and evolution of adenoviruses, J Gen Virol, 84, 2895, 10.1099/vir.0.19497-0 Pereira, 1957, Dose-response curves of toxic and infective actions of adenovirus in HeLa cell cultures, J Gen Microbiol, 17, 517, 10.1099/00221287-17-2-517 Huebner, 1956, Studies on the use of viruses in the treatment of carcinoma of the cervix, Cancer, 9, 1211, 10.1002/1097-0142(195611/12)9:6<1211::AID-CNCR2820090624>3.0.CO;2-7 Schenk, 2014, Preclinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer, Hum Gene Ther Clin Dev, 25, 7, 10.1089/humc.2013.181 Dong, 2014, ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models, Hum Gene Ther, 25, 897, 10.1089/hum.2013.229 Xu, 2015, The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer, Gene Ther, 22, 247, 10.1038/gt.2014.110 Taneja, 2015, Re: Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer, J Urol, 193, 847 Mao, 2015, Oncolytic virus carrying shRNA targeting SATB1 inhibits prostate cancer growth and metastasis, Tumour Biol, 36, 9073, 10.1007/s13277-015-3658-x Liu, 2015, Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells, Oncotarget, 6, 3055, 10.18632/oncotarget.3073 Gibson, 2015, Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors, Oncoimmunology, 4, e984523, 10.4161/2162402X.2014.984523 Piedra, 1998, Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors, Pediatrics, 101, 1013, 10.1542/peds.101.6.1013 Abbink, 2007, Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D, J Virol, 81, 4654, 10.1128/JVI.02696-06 Hemminki, 2003, A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model, Mol Ther, 7, 163, 10.1016/S1525-0016(02)00049-7 Hoffmann, 2008, Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma, J Invest Dermatol, 128, 988, 10.1038/sj.jid.5701131 Hoffmann, 2007, Evaluation of twenty human adenoviral types and one infectivity-enhanced adenovirus for the therapy of soft tissue sarcoma, Hum Gene Ther, 18, 51, 10.1089/hum.2006.132 Strauss, 2009, Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses, Cancer Res, 69, 5115, 10.1158/0008-5472.CAN-09-0645 Shashkova, 2009, Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents, Virology, 394, 311, 10.1016/j.virol.2009.08.038 Senac, 2010, Infection and killing of multiple myeloma by adenoviruses, Hum Gene Ther, 21, 179, 10.1089/hum.2009.082 Chen, 2011, Species D adenoviruses as oncolytics against B-cell cancers, Clin Cancer Res, 17, 6712, 10.1158/1078-0432.CCR-11-0968 Chen, 2011, Mining the adenovirus virome for oncolytics against multiple solid tumor types, Cancer Gene Ther, 18, 744, 10.1038/cgt.2011.47 Weaver, 2011, Characterization of species C human adenovirus serotype 6 (Ad6), Virology, 412, 19, 10.1016/j.virol.2010.10.041 Blusch, 2002, The novel early region 3 protein E3/49K is specifically expressed by adenoviruses of subgenus D: implications for epidemic keratoconjunctivitis and adenovirus evolution, Virology, 296, 94, 10.1006/viro.2002.1404 Khare, 2011, Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer, Mol Ther, 19, 1254, 10.1038/mt.2011.71 Khare, 2013, Circulating antibodies and macrophages as modulators of adenovirus pharmacology, J Virol, 87, 3678, 10.1128/JVI.01392-12 Xu, 2008, Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement, J Virol, 82, 11705, 10.1128/JVI.01320-08 Barry, 2009, Systemic delivery of therapeutic viruses, Curr Opin Mol Ther, 11, 411 Khare, 2011, Advances and future challenges in adenoviral vector pharmacology and targeting, Curr Gene Ther, 11, 241, 10.2174/156652311796150363 Doronin, 2009, Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus, Hum Gene Ther, 20, 975, 10.1089/hum.2009.028 O’Riordan, 1999, PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo, Hum Gene Ther, 10, 1349, 10.1089/10430349950018021 Croyle, 2001, “Stealth” adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung, J Virol, 75, 4792, 10.1128/JVI.75.10.4792-4801.2001 Croyle, 2002, PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver, Hum Gene Ther, 13, 1887, 10.1089/104303402760372972 Mok, 2005, Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses, Mol Ther, 11, 66, 10.1016/j.ymthe.2004.09.015 Croyle, 2005, PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile, Gene Ther, 12, 579, 10.1038/sj.gt.3302441 Hofherr, 2007, Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia, Hum Gene Ther, 18, 837, 10.1089/hum.2007.0051 Stone, 1978, Isolation of a human prostate carcinoma cell line (DU 145), Int J Cancer, 21, 274, 10.1002/ijc.2910210305 Horoszewicz, 1983, LNCaP model of human prostatic carcinoma, Cancer Res, 43, 1809 Sumida, 2005, Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein, J Immunol, 174, 7179, 10.4049/jimmunol.174.11.7179 Vogels, 2003, Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity, J Virol, 77, 8263, 10.1128/JVI.77.15.8263-8271.2003 Shashkova, 2007, Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus, Mol Ther, 15, 598, 10.1038/sj.mt.6300064 Yang, 1994, MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses, Immunity, 1, 433, 10.1016/1074-7613(94)90074-4 Horwitz, 2004, Function of adenovirus E3 proteins and their interactions with immunoregulatory cell proteins, J Gene Med, 6, S172, 10.1002/jgm.495 Lichtenstein, 2004, Functions and mechanisms of action of the adenovirus E3 proteins, Int Rev Immunol, 23, 75, 10.1080/08830180490265556 Suzuki, 2002, The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses, Clin Cancer Res, 8, 3348 Wang, 2003, E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models, Nat Biotechnol, 21, 1328, 10.1038/nbt887 Campos, 2004, Rapid construction of capsid-modified adenoviral vectors through bacteriophage lambda Red recombination, Hum Gene Ther, 15, 1125, 10.1089/hum.2004.15.1125 Weaver, 2011, Characterization of species C human adenovirus serotype 6 (Ad6), Virology, 412, 19, 10.1016/j.virol.2010.10.041 Shashkova, 2009, Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus, Mol Ther, 17, 2121, 10.1038/mt.2009.217 Shayakhmetov, 2005, Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity, J Virol, 79, 7478, 10.1128/JVI.79.12.7478-7491.2005 Parker, 2006, Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes, Blood, 108, 2554, 10.1182/blood-2006-04-008532 Hofherr, 2008, Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression, Mol Ther, 16, 1276, 10.1038/mt.2008.86 Weaver, 2013, Low seroprevalent species D adenovirus vectors as influenza vaccines, PLoS One, 8, e73313, 10.1371/journal.pone.0073313